Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ADPT with free AI briefings, catalyst countdowns, and dilution alerts.

ADPT · Adaptive Biotechnologies Corp

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$400.2M Cash on Hand
CF+ Cash Runway
Follow ADPT by email Get an email when ADPT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ADPT, unsubscribe in one click. Privacy

📣 What ADPT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Bacteriophage Prosthetic Joint Infection Phase 2 · NCT05269134 Withdrawn
Bendamustine Lymphoma Phase 2 · NCT06557330 Not yet recruiting
Anti-CD20 Monoclonal Antibody Chronic Lymphocytic Leukemia (CLL) Phase 2 · NCT04419519 Active not recruiting
Immunotherapeutic Agent Multiple Myeloma N/A · NCT05271630 Active not recruiting
Proteasome Inhibitor Multiple Myeloma N/A · NCT05271630 Active not recruiting

Also used in these trials (approved or third-party drugs, not ADPT's own candidates): Glofitamab, Mosunetuzumab, Nivolumab, Obinutuzumab, Pirtobrutinib, Rituximab, Venetoclax.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ADPT holds $400.2M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ADPT files for a raise →

👥 Who Owns ADPT

Insiders 2.9% Other 5%+ holders 18.5% Institutions (442 holders) 78.6% Public and other holders 0%
HolderTypeShares% of sharesAs of
VIKING GLOBAL INVESTORS LP 5%+ holder (13G) 29,993,708 18.53% 2026-03-31
BlackRock, Inc. Institution (13G, 5%+) 11,992,448 7.41% 2025-12-31
Chad M Robins
CEO and Chairman, Director
Insider 2,080,518 1.29% 2026-11-09
Harlan S Robins
Chief Scientific Officer
Insider 812,058 0.50% 2026-07-21
Susan Bobulsky
Chief Commercial Officer, MRD
Insider 387,475 0.24% 2026-11-11
Julie Rubinstein
President and COO · +45,731 options
Insider 377,802 0.23% 2026-11-11
Kyle Piskel
Chief Financial Officer
Insider 256,725 0.16% 2026-05-18
Francis Lo
Chief People Officer · +245,254 options
Insider 223,367 0.14% 2026-10-01
Sharon Benzeno
Chief Commercial Ofc Imm Med · +238,176 options
Insider 221,278 0.14% 2026-06-26
Peter M Neupert
Director
Insider 130,625 0.08% 2026-08-17
Katey Einterz Owen
Director
Insider 66,100 0.04% 2026-08-31
Robert Hershberg
Director
Insider 46,683 0.03% 2026-08-18

Share count 161,876,694 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ADPT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ADPT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.